Structure-Based Pharmacophore Design and Virtual Screening for Novel Tubulin Inhibitors with Potential Anticancer Activity

• Published in: Molecules (Basel, Switzerland) Switzerland), 2019-09, Vol.24 (17), p.3181
• Main Authors: Zhou, Yunjiang, Di, Bin, Niu, Miao-Miao
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Antitumor activity; Binding Sites; Cancer; cancer therapy; Cell Line, Tumor; Cell Proliferation - drug effects; Colchicine - metabolism; Drug Design; Drug Evaluation, Preclinical; Drugs; Humans; Hydrogen; Ligands; Models, Molecular; molecular docking; pharmacophore modeling; Planar structures; Polymerization; Quantitative Structure-Activity Relationship; Tubulin; Tubulin - metabolism; Tubulin Modulators - pharmacology; tubulin polymerization
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules24173181

Tubulin inhibitors have been considered as potential drugs for cancer therapy. However, their drug resistance and serious side-effects are the main reasons for clinical treatment failure. Therefore, there is still an urgent need to develop effective therapeutic drugs. Herein, a structure-based pharmacophore model was developed based on the co-crystallized structures of the tubulin with a high resolution. The model including one hydrogen-bond acceptor feature, two aromatic features, and one hydrophobic feature was further validated using the Gunner-Henry score method. Virtual screening was performed by an integrated protocol that combines drug-likeness analysis, pharmacophore mapping, and molecular docking approaches. Finally, five hits were selected for biological evaluation. The results indicated that all these hits at the concentration of 40 μM showed an inhibition of more than 50% against five human tumor cells (MCF-7, U87MG, HCT-116, MDA-MB-231, and HepG2). Particularly, hit 1 effectively inhibited the proliferation of these tumor cells, with inhibition rates of more than 80%. The results of tubulin polymerization and colchicine-site competition assays suggested that hit 1 significantly inhibited tubulin polymerization by binding to the colchicine site. Thus, hit 1 could be used as a potential chemotherapeutic agent for cancer treatment. This work also demonstrated the potential of our screening protocol to identify biologically active compounds.